Paused coronavirus vaccine trials ready to resume

Coronavirus vaccine trials conducted by AstraZeneca and Johnson & Johnson are preparing to resume, the pharmaceutical companies said Friday.
Both studies were put on hold after two volunteers who enrolled in AstraZeneca's vaccine trial developed a possible neurological side effect, and another person enrolled in J&J's study reportedly suffered a stroke. AstraZeneca, which had already restarted its trial in other parts of the world, including the United Kingdom, South Africa, and Brazil, said independent monitoring committees and international regulators agreed it was safe to resume the trial in the U.S, as well. The Food and Drug Administration reportedly did not find the vaccine candidate to be responsible for the neurological symptoms, but the agency was also unable to definitively rule out a link.
Similarly, investigators concluded the J&J volunteer's illness did not appear to be related to the vaccine candidate, although there was "no clear cause" of the incident. Paul Stoffels, the chief scientific officer at J&J, told Stat News the company could begin enrolling patients for the vaccine study — the only major one to test just a single dose — again early next week. Read more at The Washington Post and The Wall Street Journal.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Amazon's 'James Bond' deal could mean a new future for 007
In the Spotlight The franchise was previously owned by the Broccoli family
By Justin Klawans, The Week US Published
-
Why are Republicans suddenly panicking about DOGE?
TODAY'S BIG QUESTION As Trump and Musk take a chainsaw to the federal government, a growing number of Republicans worry that the massive cuts are hitting a little too close to home
By Rafi Schwartz, The Week US Published
-
What is JD Vance's Net Worth?
In Depth The vice president is rich, but not nearly as wealthy as his boss and many of his boss' appointees
By David Faris Published
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published
-
Bird flu one mutuation from human threat, study finds
Speed Read A Scripps Research Institute study found one genetic tweak of the virus could enable its spread among people
By Peter Weber, The Week US Published
-
Dark chocolate tied to lower diabetes risk
Speed Read The findings were based on the diets of about 192,000 US adults over 34 years
By Peter Weber, The Week US Published